Articles > Health magazines > Medical magazines > Cancer Weekly articles > November 2009

Article: Curis to Present at the Oppenheimer 20th Annual Healthcare Conference.(Conference news)

Article from:
Cancer Weekly
Article date:
November 10, 2009
Copyright

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, announced that the Company will be presenting at the Oppenheimer 20th Annual Healthcare Conference at 3:55 p.m. EST on November 3, 2009, at the Waldorf Astoria in New York City (see also Curis, Inc.).

Dan Passeri, Curis' President and Chief Executive Officer, will provide an overview of the status of GDC-0449, an orally-administered small molecule Hedgehog Pathway Inhibitor. GDC-0449 is currently being developed in Phase II clinical trials by Curis' collaborator Genentech, including in a pivotal Phase II trial in ...

Read all of this article with a FREE trial

Related newspaper, magazine, and journal articles:

Article: Curis Provides Update on Ongoing Basal Cell ...
Business Wire;  January 23, 2006 ;     700+ words ... ... to Curis for Curis' further development ... termination of the basal cell carcinoma drug ... treatment of basal cell carcinoma ... collaboration, Curis retained a co ... intended to treat basal cell carcinoma. In January 2005, Curis elected to exercise ...

Article: Curis Announces Dosing of First Patient in Phase I ...
Business Wire;  June 8, 2005 ;     700+ words ... ... treatment of basal cell carcinoma ... collaboration, Curis retained a co ... intended to treat basal cell carcinoma. In January 2005, Curis elected to exercise ... outcomes in our basal cell carcinoma product ... adverse results in Curis' and its strategic ...

Article: Curis Announces IND Filing for Skin Cancer; Drug candidate ...
Business Wire;  April 1, 2005 ;     700+ words ... ... topical treatment of basal cell carcinoma. Under ... collaboration, Curis retained a co ... intended to treat basal cell carcinoma. In January 2005, Curis elected to exercise ... collaboration between Curis and Genentech for a basal cell carcinoma product ...

Article: Curis Determines to Opt Out of Co-Development of ...
Business Wire;  September 1, 2006 ;     700+ words ... ... penetrate human skin. Curis has incurred approximately ... development costs under the basal cell carcinoma program through ... decisions regarding the basal cell carcinoma program ... for the treatment of basal cell carcinoma, Curis would be eligible for ...

Article: CURIS Issued U.S. Patent on Small Molecule Inhibitors of ...
Business Wire;  April 23, 2003 ;     700+ words ... ... under development by CURIS as a treatment for basal cell carcinoma, the most ... stated Dr. Lee Rubin, CURIS' Chief Scientific ... In addition to basal cell carcinoma, the Hedgehog ... said Daniel Passeri, CURIS' President and Chief ...

Article: Genentech Funds Additional Hedgehog Research at Curis; ...
Business Wire;  May 9, 2006 ;     700+ words ... ... control repair and regeneration. Curis' product development involves ... to modulate these pathways. Curis has successfully used this technology ... development arrangement for a basal cell carcinoma product candidate ... information, please visit the Curis web site at www.curis.com ...

Article: Curis Announces Genentech's Expected Initiation of Pivotal ...
Business Wire;  January 15, 2009 ;     700+ words ... ... CAMBRIDGE, Mass. -- Curis, Inc. (NASDAQ: CRIS ... metastatic or locally advanced basal cell carcinoma (BCC). Under ... collaboration agreement, Curis will receive a $6 million ... BCC patients," said Curis President and CEO Dan ... II trial in advanced basal cell carcinoma. There is ...

Article: Curis Receives Approval to Start Phase 1 Clinical Trial of ...
Business Wire;  September 5, 2001 ;     700+ words ... ... Patients an Alternative to Surgery- Curis, Inc. (NASDAQ: CRIS) today announced ... 61414 in Patients with Sporadic Basal Cell Carcinoma, the most common form of ... According to Doros Platika, MD, Curis, Inc. President and CEO, "Although ...

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!

Find articles, research, and archives